Fresenius SE & Co. KGaA (FRA:FRE) PT Set at €49.00 by The Goldman Sachs Group

The Goldman Sachs Group set a €49.00 ($57.65) price target on Fresenius SE & Co. KGaA (FRA:FRE) in a report released on Wednesday morning, Borsen Zeitung reports.

A number of other analysts also recently weighed in on FRE. Credit Suisse Group set a €44.00 ($51.76) price target on shares of Fresenius SE & Co. KGaA in a research report on Friday, July 30th. Deutsche Bank Aktiengesellschaft set a €39.00 ($45.88) price target on Fresenius SE & Co. KGaA and gave the company a neutral rating in a research note on Thursday, June 17th. Morgan Stanley set a €47.00 ($55.29) price target on Fresenius SE & Co. KGaA in a research note on Wednesday, July 14th. Barclays set a €53.00 ($62.35) price objective on Fresenius SE & Co. KGaA in a report on Friday, September 10th. Finally, Jefferies Financial Group set a €39.00 ($45.88) price target on shares of Fresenius SE & Co. KGaA in a research report on Friday, July 30th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Buy and a consensus target price of €48.38 ($56.92).

Shares of FRE opened at €41.12 ($48.38) on Wednesday. Fresenius SE & Co. KGaA has a 52-week low of €60.16 ($70.78) and a 52-week high of €80.00 ($94.12). The stock has a fifty day moving average price of €44.30 and a two-hundred day moving average price of €42.62.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

See Also: What is a dead cat bounce?

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.